Health
FDA Clears Novartis's Cosentyx as the First Anti-IL-17 Treatment for Polymyalgia Rheumatica
The approval gives patients whose disease no longer responds to steroids a new way to taper off them.
Novartis said Tuesday that the FDA approved Cosentyx for adults with polymyalgia rheumatica who respond poorly to steroids or cannot taper them.
Novartis, based in Basel, announced the approval on Tuesday, November 17, 2026. The Food and Drug Administration (FDA) approved Cosentyx (secukinumab) at a 150 milligram dose.
Who the approval covers
The approval covers adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids. It also covers patients who cannot tolerate corticosteroid taper, the gradual reduction of steroid doses.
PMR is a common inflammatory disease that primarily affects adults over 50. It causes acute pain and stiffness in the shoulders, neck and hips.
About 966,000 people are living with PMR in the United States. Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people with the disease.
Cosentyx is a fully human biologic that directly inhibits interleukin-17A (IL-17A). IL-17A is a cytokine, a signaling protein involved in the inflammation underlying several immune-mediated diseases.
The drug's existing adult approvals include psoriatic arthritis, moderate-to-severe plaque psoriasis and ankylosing spondylitis. They also include non-radiographic axial spondyloarthritis and hidradenitis suppurativa, and now PMR.
What the REPLENISH trial showed
The approval rests on REPLENISH, a pivotal Phase III trial registered as NCT05767034. The study was global, multicenter, randomized, double-blind, placebo-controlled and conducted across 27 countries.
Patients received Cosentyx 150 mg or placebo, each with a 24-week steroid taper regimen. A taper gradually lowers the steroid dose rather than stopping it at once.
The primary endpoint was met: sustained remission at Week 52 reached 40.5% on Cosentyx 150 mg. That compared with 20.5% on placebo, twice the rate, following the 24-week steroid tapering.
Sustained remission means the disease stayed controlled over time, not just at a single visit. The results were published in the New England Journal of Medicine.
Key secondary endpoints were named without values in the release. They were complete sustained remission at Week 52, the adjusted annual cumulative steroid dose, and time to first escape or rescue treatment.
Safety in the trial
Novartis said the safety profile in the PMR trial stayed consistent with Cosentyx's established profile. Serious adverse events occurred in 15.9% of patients on Cosentyx 150 mg, against 14.2% on placebo.
Hypersensitivity reactions, including eczema, dermatitis, rash and urticaria, occurred in 14% on Cosentyx against 9% on placebo. Urticaria is hives; hypersensitivity means an allergic-type reaction.
Urinary tract infections occurred in 13% on Cosentyx against 7% on placebo. One patient in the 150 mg group had a serious urinary tract infection event.
A fatal case of cryptococcal meningitis occurred in a patient treated with Cosentyx. The release does not assign that case to the 150 mg group, and this article does not either.
John Stone of Harvard Medical School and Massachusetts General Hospital, the trial's global principal investigator, said: "For too long, treatment options beyond glucocorticoids have been limited."
Stone added: "In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment."
Victor Bultó, President, US, at Novartis, said: "With this approval in PMR, our 11th US indication for Cosentyx, we are expanding those benefits to a community that has had limited treatment options for far too long."
Why steroids are the problem
Long-term steroid use is the current standard of care for PMR. Novartis said it may be associated with significant side effects and risks.
Long-term steroid use raises the risk of osteoporosis, cardiovascular disease and diabetes. Osteoporosis is bone thinning that raises fracture risk.
Relapses are frequent, affecting up to 40% of patients in the first year. That pattern helps explain why a steroid-sparing option matters for this population.
This is Cosentyx's 11th United States indication. Novartis said it builds on a profile established over more than a decade across immune-mediated diseases.
What remains unknown
Whether the steroid-sparing result holds in routine practice beyond the trial's Week 52 endpoint is unknown.
No price for the PMR use was disclosed in the release, so the cost to patients and payers is unanswered. How insurers cover the new indication is also unknown.
The longer-term safety picture in PMR beyond the trial period is not yet established. The fatal meningitis case is reported without an assigned treatment arm in the release.
The decisions that come next
What to watch: regulatory reviews of the PMR indication are ongoing in other countries, including Japan. Novartis said it filed the REPLENISH data for review in Japan and other countries.
The indication is already approved in the European Union, so the United States decision closes one major market gap.
Sources & evidence
Source checked1 source · 11 figures
Figure receipts
Sources
Sources used for this piece.
As of Tuesday, Nov. 17, 2026.

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

